Biotech stocks are always interesting from a trading perspective. With dozens of companies in the clinical-stage, positive news from trials can be a big catalyst for a scintillating rally. Biotech stocks were however subdued in a post-pandemic world with focus shifting to other sectors. This has translated into undervalued in several interesting biotech stocks under $10.
This column focuses on three biotech stocks under $10 that have impending catalysts. In most cases, the catalyst related to trial outcomes that set stage for commercialization of a molecular entity. Besides the meme frenzy, let’s discuss the fundamental reasons to be bullish on these ideas.
This post appeared first on InvestorPlace.